Summary
Pfizer Inc. (PFE) filed an 8-K report on January 28, 2014, to announce its financial results for the fourth quarter and full year ended December 31, 2013. The report primarily serves to incorporate by reference a press release issued by the company on the same date, which contains the detailed financial performance data. Investors should refer to this press release, attached as Exhibit 99 to the 8-K, for specific figures regarding revenue, earnings, and other key financial metrics for the period. While the 8-K itself does not contain the detailed financial tables, it formally submits the press release for public record and regulatory compliance. The disclosed results are crucial for understanding Pfizer's operational performance, profitability trends, and overall financial health heading into 2014. Investors are advised to carefully review the referenced press release for comprehensive insights into Pfizer's business and outlook.
Key Highlights
- 1Pfizer Inc. announced its Q4 and Full-Year 2013 financial results on January 28, 2014.
- 2The 8-K filing serves to officially submit the press release containing these results.
- 3Investors must consult the attached press release (Exhibit 99) for detailed financial performance data.
- 4The filing covers financial results for both the fourth quarter and the entire fiscal year 2013.
- 5This report is a standard disclosure mechanism for announcing quarterly and annual financial performance.